Search

Your search keyword '"Fushimi, Kazumi"' showing total 22 results
Start Over Author "Fushimi, Kazumi"
22 results on '"Fushimi, Kazumi"'

9. Peptide vaccine-treated, long-term surviving cancer patients harbor self-renewing tumor-specific CD8+ T cells.

Author

Mizukoshi, Eishiro, Nakagawa, Hidetoshi, Tamai, Toshikatsu, Kitahara, Masaaki, Fushimi, Kazumi, Nio, Kouki, Terashima, Takeshi, Iida, Noriho, Arai, Kuniaki, Yamashita, Tatsuya, Yamashita, Taro, Sakai, Yoshio, Honda, Masao, and Kaneko, Shuichi

Subjects
PEPTIDES, T cells, CANCER patients, AP-1 transcription factor, IMMUNOLOGIC memory, CYTOTOXIC T cells, HEPATOCELLULAR carcinoma
Abstract

The behaviors and fates of immune cells in cancer patients, such as dysfunction and stem-like states leading to memory formation in T cells, are in intense focus of investigation. Here we show, by post hoc analysis of peripheral blood lymphocytes of hepatocellular carcinoma patients previously undergoing vaccination with tumour-associated antigen-derived peptides in our clinical trials (registration numbers UMIN000003511, UMIN000004540, UMIN000005677, UMIN000003514 and UMIN000005678), that induced peptide-specific T cell responses may persist beyond 10 years following vaccination. Tracking TCR clonotypes at the single cell level reveals in two patients that peptide-specific long-lasting CD8+ T cells acquire an effector memory phenotype that associates with cell cycle-related genes (CCNA2 and CDK1), and are characterized by high expression of IL7R, SELL, and NOSIP along with a later stage promotion of the AP-1 transcription factor network (5 years or more past vaccination). We conclude that effective anti-tumor immunity is governed by potentially proliferative memory T cells, specific to cancer antigens. The success of peptide vaccine treatment in cancer relies on the build-up of an efficient cytotoxic T cell response against the tumour antigen. Authors show here that tumour-specific memory CD8 T cells are able to persist and possibly even proliferate in the peripheral blood of long-surviving hepatocellular carcinoma patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

11. The Characteristics of the Immune Cell Profiles in Peripheral Blood in Cholangiocarcinoma Patients

Author

Kida, Akihiko, primary, Mizukoshi, Eishiro, additional, Kido, Hidenori, additional, Toyama, Tadashi, additional, Terashima, Takeshi, additional, Arai, Kuniaki, additional, Yamashita, Tatsuya, additional, Fushimi, Kazumi, additional, Yamashita, Taro, additional, Sakai, Yoshio, additional, Honda, Masao, additional, Uchiyama, Akio, additional, Sakai, Akito, additional, Shimizu, Koichi, additional, and Kaneko, Shuichi, additional

Published
2021
Full Text
View/download PDF

12. Abscopal Effect of Frozen Autograft Reconstruction Combined with an Immune Checkpoint Inhibitor Analyzed Using a Metastatic Bone Tumor Model

Author

Yonezawa, Noritaka, primary, Murakami, Hideki, additional, Demura, Satoru, additional, Kato, Satoshi, additional, Miwa, Shinji, additional, Yoshioka, Katsuhito, additional, Shinmura, Kazuya, additional, Yokogawa, Noriaki, additional, Shimizu, Takaki, additional, Oku, Norihiro, additional, Kitagawa, Ryo, additional, Handa, Makoto, additional, Annen, Ryohei, additional, Kurokawa, Yuki, additional, Fushimi, Kazumi, additional, Mizukoshi, Eishiro, additional, and Tsuchiya, Hiroyuki, additional

Published
2021
Full Text
View/download PDF

13. Fatty acid-driven modifications in T-cell profiles in non-alcoholic fatty liver disease patients

Author

Seike, Takuya, primary, Mizukoshi, Eishiro, additional, Yamada, Kazutoshi, additional, Okada, Hikari, additional, Kitahara, Masaaki, additional, Yamashita, Tatsuya, additional, Arai, Kuniaki, additional, Terashima, Takeshi, additional, Iida, Noriho, additional, Fushimi, Kazumi, additional, Yamashita, Taro, additional, Sakai, Yoshio, additional, Honda, Masao, additional, Harada, Kenichi, additional, and Kaneko, Shuichi, additional

Published
2020
Full Text
View/download PDF

14. Characteristics of Impaired Dendritic Cell Function in Patients With Hepatitis B Virus Infection

Author

Yonejima, Atsushi, primary, Mizukoshi, Eishiro, additional, Tamai, Toshikatsu, additional, Nakagawa, Hidetoshi, additional, Kitahara, Masaaki, additional, Yamashita, Tatsuya, additional, Arai, Kuniaki, additional, Terashima, Takeshi, additional, Iida, Noriho, additional, Fushimi, Kazumi, additional, Okada, Hikari, additional, Yamashita, Taro, additional, Sakai, Yoshio, additional, Honda, Masao, additional, and Kaneko, Shuichi, additional

Published
2019
Full Text
View/download PDF

15. Characteristics of Immune Response to Tumor‐Associated Antigens and Immune Cell Profile in Patients With Hepatocellular Carcinoma

Author

Inada, Yuki, primary, Mizukoshi, Eishiro, additional, Seike, Takuya, additional, Tamai, Toshikatsu, additional, Iida, Noriho, additional, Kitahara, Masaaki, additional, Yamashita, Tatsuya, additional, Arai, Kuniaki, additional, Terashima, Takeshi, additional, Fushimi, Kazumi, additional, Yamashita, Taro, additional, Honda, Masao, additional, and Kaneko, Shuichi, additional

Published
2018
Full Text
View/download PDF

19. Expression of chondroitin-glucuronate C5-epimerase and cellular immune responses in patients with hepatocellular carcinoma

Author

Mizukoshi, Eishiro, Fushimi, Kazumi, Arai, Kuniaki, Yamashita, Tatsuya, Honda, Masao, Kaneko, Shuichi, Mizukoshi, Eishiro, Fushimi, Kazumi, Arai, Kuniaki, Yamashita, Tatsuya, Honda, Masao, and Kaneko, Shuichi

Abstract

Background & Aims: Chondroitin-glucuronate C5-epimerase is an enzyme that converts D-glucuronic acid to L-iduronic acid residues in dermatan sulphate biosynthesis. It is also identified to be a tumour-associated antigen recognized by cytotoxic T cells (CTLs) and its enhanced expression in many cancers has been reported. In the present study, we investigated the usefulness of this molecule as an immunotherapeutic target in hepatocellular carcinoma (HCC). Methods: The expression of chondroitin-glucuronate C5-epimerase in hepatoma cell lines and HCC tissues was confirmed by immunofluorescence and immunohistochemical analysis. CTL responses were investigated by several immunological techniques using peripheral blood mononuclear cells (PBMCs) or tumour-infiltrating lymphocytes. To determine the safety of immunotherapy using chondroitin-glucuronate C5-epimerase-derived peptide, 12 patients with HCC were administered s.c. vaccinations of the peptides and analysed. Results: Chondroitin-glucuronate C5-epimerase was expressed in HCC cell lines and human tissues including alpha-foetoprotein (AFP)-negative individuals. Chondroitin-glucuronate C5-epimerase-specific CTLs could be generated by stimulating PBMCs of HCC patients with peptides and they showed cytotoxicity against HCC cells expressing the protein. The frequency of CTL precursors investigated by enzyme-linked immunospot (ELISPOT) assay was 0-34 cells/3 × 10 5 PBMCs and the infiltration of interferon-gamma-producing CTLs into the tumour site was confirmed. In the vaccination study, no severe adverse events were observed and the peptide-specific CTLs were induced in 4 of 12 patients tested. Conclusions: Chondroitin-glucuronate C5-epimerase is a potential candidate for tumour antigen with immunogenicity and the peptides derived from this antigen could be useful in HCC immunotherapy. © 2012 John Wiley & Sons A/S.

Published
2017

20. Cellular Immune Responses for Squamous Cell Carcinoma Antigen Recognized by T Cells 3 in Patients with Hepatocellular Carcinoma

Author

Kaji, Kiichiro, primary, Mizukoshi, Eishiro, additional, Yamashita, Tatsuya, additional, Arai, Kuniaki, additional, Sunagozaka, Hajime, additional, Fushimi, Kazumi, additional, Nakagawa, Hidetoshi, additional, Yamada, Kazutoshi, additional, Terashima, Takeshi, additional, Kitahara, Masaaki, additional, and Kaneko, Shuichi, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results